Chronic Active Hepatitis Treated with 6-Mercaptopurine—Sustained Remission
Authors: JOSEPH E. GEENEN
Journal: Annals of Internal Medicine (1966)

Case Studies1 December 1966Chronic Active Hepatitis Treated with 6-Mercaptopurine—Sustained RemissionJOSEPH E. GEENEN, M.D., GEORGE T. HENSLEY, M.D., DANIEL H. WINSHIP, M.D.JOSEPH E. GEENEN, M.D.Search for more papers by this author, GEORGE T. HENSLEY, M.D.Search for more papers by this author, DANIEL H. WINSHIP, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-65-6-1277 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThere is general agreement regarding the clinical and pathological features of chronic active hepatitis (1)—lupoid hepatitis (2), plasma cell hepatitis (3), active juvenile cirrhosis (4)—but the efficacy of any type of therapy has yet to be established. Suppression of symptomatic and biochemical manifestations is often achieved during glucocorticoid administration (3-7), but proof that these drugs affect the ultimate prognosis favorably is lacking. A few recent reports (5, 8-10) suggest that some patients may benefit from the administration of purine antagonists (6-mercaptopurine, azathioprine, 6-thioguanine). In no reported case of well-established chronic active hepatitis thus treated, however, has the remission been sustained...References1. POPPER H: What is chronic hepatitis? Gastroenterology 50: 444, 1966. CrossrefMedlineGoogle Scholar2. MACKAYTAFTCOWLING IRLIDC: Lupoid hepatitis. Lancet 2: 1323, 1956. CrossrefGoogle Scholar3. PAGEGOOD ARRA: Plasma-cell hepatitis, with special attention to steroid therapy. Amer. J. Dis. Child. 99: 288, 1960. Google Scholar4. READSHERLOCKHARRISON AESCV: Active "juvenile" cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. Gut 4: 378, 1963. CrossrefMedlineGoogle Scholar5. MACKAYWOOD IRIJ: The course and treatment of lupoid hepatitis. Gastroenterology 45: 4, 1963. CrossrefMedlineGoogle Scholar6. KERNVINNIKSTRUTHERSHILL FIEJERB: The treatment of chronic hepatitis with adrenal cortical hormones. Amer. J. Med. 35: 310, 1963. CrossrefMedlineGoogle Scholar7. MISTILISSCHIFF SPL: Steroid therapy in chronic hepatitis. Arch. Intern. Med. (Chicago) 113: 54, 1964. CrossrefMedlineGoogle Scholar8. GOODMANWOLFFCARPENTERANDERSONBRANDRISS HCSMRRBRMW: Studies on the effect of antimetabolites in nephrosis, other non-neoplastic diseases, and experimental animals. Ann. Intern. Med. 59: 398, 1963. LinkGoogle Scholar9. PAGECONDIEGOOD ARRMRA: Suppression of plasma cell hepatitis with 6-mercaptopurine. Amer. J. Med. 36: 200, 1964. CrossrefMedlineGoogle Scholar10. MACKAYWEIDENUNGAR IRSB: Treatment of active chronic hepatitis and lupoid hepatitis with 6-mercaptopurine and azothioprine. Lancet 1: 899, 1964. CrossrefMedlineGoogle Scholar11. EINHORNDAVIDSOHN MI: Hepatotoxicity of mercaptopurine. JAMA 188: 802, 1964. CrossrefMedlineGoogle Scholar12. BURCHENALELLISON JHRR: Symposium on the experimental pharmacology and clinical use of antimetabolites. IX. The pyrimidine and purine antagonists. Clin. Pharmacol. Ther. 2: 523, 1961. CrossrefMedlineGoogle Scholar13. CLARKHSIAHUNTSMAN PAYERG: Toxic complications of treatment with 6-mercaptopurine; two cases with hepatic necrosis and intestinal ulceration. Brit. Med. J. 1: 393, 1960. CrossrefMedlineGoogle Scholar14. MACLACHLANRODNANCOOPERFENNELL MJGPWMRH: Chronic active ("lupoid") hepatitis; a clinical, serological, and pathological study of 20 patients. Ann. Intern. Med. 62: 425, 1965. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOSEPH E. GEENEN, M.D.; GEORGE T. HENSLEY, M.D.; DANIEL H. WINSHIP, M.D.Affiliations: Milwaukee, WisconsinFrom the Departments of Medicine and Pathology, Marquette University School of Medicine and Milwaukee County General Hospital, Milwaukee, Wis.Requests for reprints should be addressed to Joseph E. Geenen, M.D., Racine Medical Clinic, 5625 Washington Ave., Racine, Wis. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunosuppressive TherapyCytotoxic Drugs in Treatment of Nonmalignant DiseasesALFRED D. STEINBERG, M.D., PAUL H. PLOTZ, M.D., SHELDON M. WOLFF, M.D., F.A.C.P., VERNON G. WONG, M.D., SAUL G. AGUS, M.D., JOHN L. DECKER, M.D., F.A.C.P.Antimetabolite therapy in the post-myocardial-infarction syndromeMechanisms of Action of Drugs Affecting Immune ResponsesImmunpathogenese chronisch-entzündlicher LebererkrankungenCorticosteroids and immunosuppressive drugs in chronic evolutive hepatitis treatmentAlterations in immunologic mechanisms in diseases of the gastrointestinal tractActive chronic hepatitisClassification and Treatment of Chronic Active Liver DiseaseTHE TREATMENT OF ACTIVE CHRONIC HEPATITIS WITH 6-MERCAPTOPURINE AND AZATHIOPRINE 1 December 1966Volume 65, Issue 6Page: 1277-1283KeywordsChronic hepatitisCirrhosisDrug administrationDrugsHepatitisHepatitis EHospital medicinePlasma cellsPurines ePublished: 1 December 2008 Issue Published: 1 December 1966 PDF downloadLoading ...